SK697A3 - Method for preparing 4-acetoxy-2'alpha'-benzoyloxy-5'beta',20- -epoxy-1,7'beta',10'beta'-trihydroxy-9-oxo-tax-11-en-13'alpha'- -yl(2r,3s)-3-tert-butoxycarbonylamino-2-hydroxy-3- -phenylpropionate trihydrate - Google Patents
Method for preparing 4-acetoxy-2'alpha'-benzoyloxy-5'beta',20- -epoxy-1,7'beta',10'beta'-trihydroxy-9-oxo-tax-11-en-13'alpha'- -yl(2r,3s)-3-tert-butoxycarbonylamino-2-hydroxy-3- -phenylpropionate trihydrate Download PDFInfo
- Publication number
- SK697A3 SK697A3 SK6-97A SK697A SK697A3 SK 697 A3 SK697 A3 SK 697A3 SK 697 A SK697 A SK 697A SK 697 A3 SK697 A3 SK 697A3
- Authority
- SK
- Slovakia
- Prior art keywords
- beta
- benzoyloxy
- trihydroxy
- acetoxy
- hydroxy
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 13
- 238000002425 crystallisation Methods 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 230000008025 crystallization Effects 0.000 claims description 6
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims 1
- PSSVSAXRAMDXPH-DELBANIYSA-N O.O.O.C(C)(C)(C)OC(=O)N[C@H]([C@H](C(=O)O)O)C1=CC=CC=C1 Chemical compound O.O.O.C(C)(C)(C)OC(=O)N[C@H]([C@H](C(=O)O)O)C1=CC=CC=C1 PSSVSAXRAMDXPH-DELBANIYSA-N 0.000 abstract 1
- VOXXWSYKYCBWHO-UHFFFAOYSA-N 3-phenyllactic acid Chemical compound OC(=O)C(O)CC1=CC=CC=C1 VOXXWSYKYCBWHO-UHFFFAOYSA-N 0.000 description 7
- 239000008213 purified water Substances 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- 239000013078 crystal Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 150000004684 trihydrates Chemical class 0.000 description 2
- OZUCDJFMALKZOS-UHFFFAOYSA-N 2-(butoxycarbonylamino)-2-hydroxy-3-phenylpropanoic acid Chemical compound CCCCOC(=O)NC(O)(C(O)=O)CC1=CC=CC=C1 OZUCDJFMALKZOS-UHFFFAOYSA-N 0.000 description 1
- BQGQGFJBNHUYLS-UHFFFAOYSA-N 2-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)NC(O)(C(O)=O)CC1=CC=CC=C1 BQGQGFJBNHUYLS-UHFFFAOYSA-N 0.000 description 1
- ZVAFCKLQJCZGAP-UHFFFAOYSA-N 2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)C(O)=O)C1=CC=CC=C1 ZVAFCKLQJCZGAP-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Epoxy Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Spôsob prípravy trihydrátu (2R,3S)-4-acetoxy-2a-benzoyloxy-5B120-epoxy-l,7B,10B-trihydroxy-9-oxo-tax-ll-én-13a-yl-3terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátuA process for the preparation of the trihydrate of (2R, 3S) 4-acetoxy-2-benzoyloxy-5 B 1 20-epoxy-7.beta, 10.beta.-trihydroxy-9-oxo-tax-ll-en-13-yl-2-3terc.butoxykarbonylamino hydroxy-3-phenylpropionate
Oblasť technikyTechnical field
Vynález sa týka spôsobu prípravy trihydrátu 4-acetoxy-2abenzoyloxy-5B,20-epoxy-l,7B,10B-trihydroxy-9-oxo-tax-ll-én-13ayl-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu s konfiguráciou (2R,3S).The present invention relates to a process for the preparation of 4-acetoxy-2-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11-ene-3-yl-3-tert-butoxycarbonylamino-2-hydroxy-3- phenylpropionate (2R, 3S).
Doterajší stav technikyBACKGROUND OF THE INVENTION
V európskych patentoch EP-0 253 738 a EP-0 336 841 je opísaný (2R,3S)-4-acetoxy-2a-benzoyloxy-5B,20-epoxy-l,7B,10Btrihydroxy-9-oxo-tax-ll-én-13a-yl-3-terc.butoxykarbonylamino-EP-0 253 738 and EP-0 336 841 disclose (2R, 3S) -4-acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11- en-13-yl-3-terc.butoxykarbonylamino-
2-hydroxy-3-fenylpropionát, ktorý má protirakovinové a protileukemické vlastnosti, pričom v týchto patentových dokumentoch je tiež opísaný spôsob prípravy tejto zlúčeniny.2-hydroxy-3-phenylpropionate having anti-cancer and anti-leukemic properties, and a process for preparing the compound is also described in these patents.
Zistilo sa, že trihydrát (2R,3S)-4-acetoxy-2a-benzoyloxy5B,20-epoxy-l,7B,10B-trihydroxy-9-oxo-tax-ll-én-13a-yl-3-terc. butoxykarbonylamino-2-hydroxy-3-fenylpropionátu má výrazne lepšiu stabilitu ako rovnaký produkt v bezvodom stave.(2R, 3S) -4-Acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11-en-13a-yl-3-tert. butoxycarbonylamino-2-hydroxy-3-phenylpropionate has significantly better stability than the same anhydrous product.
Podstata vynálezuSUMMARY OF THE INVENTION
Podlá vynálezu sa môže trihydrát (2R,3S)-4-acetoxy-2a-benzoyloxy-5B,20-epoxy-l,7B,10B-trihydroxy-9-oxo-tax-ll-én-13ayl-3-terc .butoxykarbonylamino-2-hydroxy-3-fenylpropionátu získať po kryštalizácii (2R,3S)-4-acetoxy-2a-benzoyloxy-5B,20epoxy-1,7B,10B-trihydroxy-9-oxo-tax-ll-én-13a-yl-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu zo zmesi vody a alifatického alkoholu obsahujúceho 1 až 3 atómy uhlíka a následným sušením získaného produktu pri stanovených teplotných, tlakových a vlhkostných podmienok.According to the invention, (2R, 3S) -4-acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11-ene-13ayl-3-tert-butoxycarbonylamino trihydrate can be Of 2-hydroxy-3-phenylpropionate obtained after crystallization of (2R, 3S) -4-acetoxy-2a-benzoyloxy-5B, 20epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11-en-13a-yl -3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate from a mixture of water and an aliphatic alcohol containing 1 to 3 carbon atoms, followed by drying the product obtained under specified temperature, pressure and humidity conditions.
Po uskutočnení spôsobu podľa vynálezu môže byť výhodné najmä:After carrying out the process according to the invention, it may in particular be advantageous to:
rozpustenie (2R,3S)-4-acetoxy-2a-benzoyloxy-5B,20-epoxy1,7β,106-trihydroxy-9—oxo-tax-ll-én—13a—yl-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu, ktorý sa predbežne prečistil chromatograficky, v alifatickom alkohole obsahujúcom 1 až 3 atómy uhlíka pri teplote, ktorá sa pohybuje výhodne medzi 40 a 60 °C,dissolution of (2R, 3S) -4-acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7β, 106-trihydroxy-9-oxo-tax-11-en-13a-yl-3-tert-butoxycarbonylamino-2-hydroxy -3-phenylpropionate, which has been previously purified by chromatography, in an aliphatic alcohol containing 1 to 3 carbon atoms at a temperature preferably between 40 and 60 ° C,
- prípadné odstránenie zvyškových chromatografických rozpúšťadiel ko-destiláciou pri zníženom tlaku, pričom sa objem oddestilovaného rozpúšťadla nahradí čistým alkoholom,- the optional removal of residual chromatographic solvents by co-distillation under reduced pressure, replacing the volume of the distilled solvent with pure alcohol,
- pridanie prípadne prečistenej vody pri rovnakej teplote,- addition of possibly purified water at the same temperature,
- a po prípadnom vyvolaní kryštalizácie zaočkovaním a ochladení na teplotu blízku 0 °C oddelenie získaných kryštálov trihydrátu (2R,3S)-4-acetoxy-2a-benzoyloxy-56,20-epoxy-l,76,10B-trihydroxy-9-oxo-tax-ll-én-13a-yl-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu, ktorý sa takto získal, a následné vysušenie pri zníženom tlaku pod atmosférou s regulovanou vlhkosťou.- and, if necessary, by crystallization by seeding and cooling to a temperature close to 0 ° C, separation of the obtained (2R, 3S) -4-acetoxy-2a-benzoyloxy-56,20-epoxy-1,76,10B-trihydroxy-9-oxo trihydrate crystals -tax-11-en-13a-yl-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate thus obtained, followed by drying under reduced pressure under a controlled humidity atmosphere.
Všeobecne sa (2R,3S)-4-acetoxy-2a-benzoyloxy-56,20-epoxy1,76,10B-trihydroxy-9-oxo-tax-ll-én-13a-yl-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionát v prečistenom stave rozpustí v prebytku alifatického alkoholu. Výhodne je množstvo alkoholu 8 až 12 hmotnostných dielov, vztiahnuté na jeden hmotnostný diel (2R,3S)-4-acetoxy-2a-benzoyloxy-56,20-epoxy1,76,10B-trihydroxy-9-oxo-tax-ll-én-13a-yl-3-terc.butoxykarbony1amino-2-hydroxy-3-fenylpropionátu.Generally, (2R, 3S) -4-acetoxy-2a-benzoyloxy-56,20-epoxy-1,76,10B-trihydroxy-9-oxo-tax-11-en-13a-yl-3-tert-butoxycarbonylamino-2- The hydroxy-3-phenylpropionate is dissolved in the excess aliphatic alcohol in the purified state. Preferably, the amount of alcohol is 8 to 12 parts by weight, based on 1 part by weight of (2R, 3S) -4-acetoxy-2a-benzoyloxy-56,20-epoxy-1,76,10B-trihydroxy-9-oxo-tax-11-ene -13?-yl-3-terc.butoxykarbony1amino-2-hydroxy-3-phenylpropionate.
Všeobecne sa oddestilovanie alkoholu uskutočňuje pri zníženom tlaku pri teplote blízkej 40 °C a to až do okamihu, kedy sa získa hustý sirup, ktorého miešanie je obťažné. Je výhodné opakovať túto operáciu, ktorá vedie k odstráneniu zvyškových rozpúšťadiel obsiahnutých v použitom prečistenom produkte , niekoľkokrát.Generally, the distillation of the alcohol is carried out under reduced pressure at a temperature close to 40 ° C until a thick syrup is obtained which is difficult to mix. It is advantageous to repeat this operation several times to remove residual solvents contained in the purified product used.
Keď sa odstránenie zvyšných rozpúšťadiel ukončí, získaný sirup sa vyberie alkoholom použitom v množstve, ktoré sa rovnáWhen the removal of the remaining solvents is complete, the syrup obtained is taken up with an alcohol used in an amount equal to
3,5 až 6 hmotnostným dielom, vztiahnuté na jeden hmotnostný diel (2R, 3S) -4-acetoxy-2a-benzoyloxy-5B, 20-epoxy-l, 7B, 10B- trihydroxy-9-oxo-tax-11-én-13 α-y 1-3-terc.butoxykarbony1amino-3.5 to 6 parts by weight, based on 1 part by weight of (2R, 3S) -4-acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11-ene -13 α-γ 1-3-tert-butoxycarbonylamino-
2-hydroxy-3-fenylpropionátu.2-hydroxy-3-phenylpropionate.
Po prípadnom odstránení nerozpustných nečistôt filtráciou sa pridá voda, výhodne prečistená, a to v takom množstve, aby hmotnostný pomer voda/alkohol bol blízky hodnote 2/1.After optionally removing the insoluble impurities by filtration, water, preferably purified water, is added in an amount such that the water / alcohol weight ratio is close to 2/1.
Kryštalizácia sa vyvolá zaočkovaním a zmes sa pozvoľne ochladí až na teplotu blízku 0 °C.Crystallization is induced by seeding and the mixture is cooled slowly to a temperature close to 0 ° C.
Vykryštalizovaný trihydrát (2R,3S)-4-acetoxy-2a-benzoyloxy-5B,20-epoxy-l,7B,10B-trihydroxy-9-oxo-tax-ll-én-13a-yl-3terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu sa oddelí, výhodne filtráciou alebo odstredením, následne sa vysuší. Sušenie sa uskutočňuje pri zníženom tlaku v rozmedzí medzi 4 a 7 kPa, pri teplote blízkej 40 °C a pod atmosférou s regulovanou vlhkosťou, pričom relatívna vlhkosť je blízka 80 %.Crystallized (2R, 3S) -4-acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11-en-13a-yl-3-tert-butoxycarbonylamino-2- The hydroxy-3-phenylpropionate is separated, preferably by filtration or centrifugation, and subsequently dried. Drying is carried out under reduced pressure between 4 and 7 kPa, at a temperature close to 40 ° C and under a controlled humidity atmosphere, the relative humidity being close to 80%.
Na uskutočnenie spôsobu podľa vynálezu je výhodné uskutočniť kryštalizáciu v prítomnosti kyseliny askorbovej, ktorá sa pridá pri rozpúšťaní prečisteného (2R,3S)-4-acetoxy2a-benzoyloxy-5B,20-epoxy-l,7β,10B-trihydroxy-9-oxo-tax-ll-én13a-yl-3-terc.butoxykarbonylamino-2-hydroxy-3-f enylpropionátu v alkohole. Môže sa použiť až 1 % hmotnosti kyseliny askorbovej .For carrying out the process of the invention, it is preferable to carry out crystallization in the presence of ascorbic acid, which is added in the dissolution of purified (2R, 3S) -4-acetoxy-2? -Benzoyloxy-5B, 20-epoxy-1,7β, 10B-trihydroxy-9-oxo tax-11-en-13a-yl-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate in alcohol. Up to 1% by weight of ascorbic acid may be used.
Na uskutočnenie spôsobu podľa vynálezu je obzvlášť výhodné použiť ako alkohol etanol.It is particularly preferred to use ethanol as the alcohol for carrying out the process according to the invention.
Štruktúra trihydrátu (2R,3S)-4-acetoxy-2a-benzoyloxy-5B,20-epoxy-l,7B,10B-trihydroxy-9-oxo-tax-ll-én-13a-yl-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu je potvrdená rôntgenovou difrakciou, termogravimetrickou analýzou a diferenčnou kalorimetrickou analýzou.(2R, 3S) -4-Acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11-en-13a-yl-3-tert-butoxycarbonylamino- 2-hydroxy-3-phenylpropionate is confirmed by X-ray diffraction, thermogravimetric analysis and differential calorimetric analysis.
Takto termogravimetrická analýza ukazuje 6,1% úbytok hmotnosti v rozsahu teplôt medzi 40 a 140 °C, čo zodpovedá trom molekulám vody na jednu molekulu (2R,3S)-4-acetoxy-2abenzoyloxy-5B,20-epoxy-l,7B,10B-trihydroxy-9-oxo-tax-ll-én13a-yl-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu.Thus, thermogravimetric analysis shows a 6.1% weight loss in the temperature range between 40 and 140 ° C, corresponding to three water molecules per molecule of (2R, 3S) -4-acetoxy-2-benzoyloxy-5B, 20-epoxy-1,7B, 10.beta.-trihydroxy-9-oxo-tax-ll-EN13-yl-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate.
Metóda stanovenia merného obsahu vody a hydratačnej vody diferenčnou kalorimetrickou analýzou ukazuje neprítomnosť neviazanej vody a endotermický signál pri teplote 132,6 °C zodpovedá disociácii hydrátu.The method of determination of specific water content and hydration water by differential calorimetry analysis shows the absence of unbound water and the endothermic signal at 132.6 ° C corresponds to the dissociation of the hydrate.
Trihydrát (2R,3S)-4-acetoxy-2a-benzoyloxy-5B,20-epoxy1,7B,10B-trihydroxy-9-oxo-tax-ll-én-13a-yl-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu už nie je hygroskoPický.(2R, 3S) -4-Acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11-en-13a-yl-3-tert-butoxycarbonylamino-2-hydroxy trihydrate -3-phenylpropionate is no longer hygroscopic.
Štúdie stability ukazujú, že trihydrát (2R,3S)-4-acetoxy2a-benzoyloxy-5B,20-epoxy-l,7B,10B-trihydroxy-9-oxo-tax-ll-én13 α-y1-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu ukazujú, že je stabilná pri teplote 4 °C, 25 °C a 35 °C v atmosfére s 90% relatívnou vlhkosťou až počas 18 mesiacov, bez toho, aby v priebehu tohto času prišlo k modifikácii jeho kryštalickej formy.Stability studies show that (2R, 3S) -4-acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11-ene-13-γ-3-tert-butoxycarbonylamino trihydrate -2-hydroxy-3-phenylpropionate show that it is stable at 4 ° C, 25 ° C and 35 ° C in an atmosphere with 90% relative humidity for up to 18 months without any modification of its crystalline form.
Pri rovnakých podmienkach prechádza (2R,3S)-4-acetoxy-2abenzoyloxy-5B,20-epoxy-l,7B,10B-trihydroxy-9-oxo-tax-ll-én-13ayl-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionát v bezvodej forme, ktorý má odlišnú kryštalickú formu, pozvoľna do trihydrátovej formy.Under the same conditions, (2R, 3S) -4-acetoxy-2-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11-ene-13ayl-3-tert-butoxycarbonylamino-2- hydroxy-3-phenylpropionate in anhydrous form, which has a different crystalline form, is slowly formed into the trihydrate form.
V nasledujúcej časti opisu bude vynález bližšie objasnený pomocou príkladov jeho konkrétneho uskutočnenia, pričom tieto príklady majú len ilustračný charakter a nijako neobmedzujú rozsah vynálezu, ktorý je jednoznačne definovaný formuláciou patentových nárokov.In the following, the invention will be explained in more detail by way of examples of a specific embodiment thereof, these examples being illustrative only and not in any way limiting of the scope of the invention, which is clearly defined by the wording of the claims.
Príklady uskutočnenia vynálezuDETAILED DESCRIPTION OF THE INVENTION
Príklad 1Example 1
Do reaktora bez prístupu svetla sa zavedie 303 g (2R,3S)-303 g of (2R, 3S) -
4-acetoxy-2a-benzoyloxy-5B,20-epoxy-l,7β,10B-trihydroxy-9-oxotax-ll-én-13a-yl-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu s čistotou 92,4 % (0,314 molu) a 2,875 kg absolút- neho etanolu (d = 0,79). Získaná zmes sa zohrieva na teplotu 40 °C až do okamihu, kedy sa dosiahne úplne rozpustenie (2R,3S)-4-acetoxy-2a-benzoyloxy-5fi,20-epoxy-l, 7B,10B-trihydroxy-9oxo-tax-ll-én-13a-yl-3-terc.butoxykarbonylamino-2-hydroxy-3fenylpropionátu. Potom sa destiluje etanol pri zníženom tlaku 12 kPa až do okamihu, kedy sa získa sirup, ktorý je na samej hranici miešateľnosti. K sirupu sa pridá 0,983 kg etanolu a destilácia sa opakuje pri rovnakých podmienkach. K získanému sirupu sa pridá 1,257 kg etanolu a zmes sa zohrieva na teplotu 50 °C až do úplného rozpustenia pevného podielu. Zmes sa prefiltruje za tepla, následne sa k filtrátu pridá v priebehu jednej hodiny 4,39 kg prečistenej vody pri udržovaní teploty 50 °C. Po vyvolaní kryštalizácie zaočkovaním sa zmes ochladí na teplotu 0 eC v priebehu 4 hodín. Vylúčené kryštály sa oddelia filtráciou, premyjú 0,909 kg a potom 0,606 kg zmesi etanolu a vody v hmotnostnom pomere 1:2, následne sa vysušia pri teplote 38 °C pri zníženom tlaku (5,07 kPa) v atmosfére s 80% relatívnou vlhkosťou v priebehu 48 hodín. Takto sa získa4-Acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7β, 10B-trihydroxy-9-oxotax-11-en-13a-yl-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate with a purity of 92 , 4% (0.314 mol) and 2.875 kg of absolute ethanol (d = 0.79). The resulting mixture is heated to 40 ° C until complete dissolution of (2R, 3S) -4-acetoxy-2α-benzoyloxy-5α, 20-epoxy-1,7B, 10B-trihydroxy-9oxo-tax- ll-en-13-yl 3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate. Ethanol is then distilled under reduced pressure of 12 kPa until a syrup is obtained which is at the very limit of miscibility. 0.983 kg of ethanol are added to the syrup and the distillation is repeated under the same conditions. 1.257 kg of ethanol are added to the obtained syrup and the mixture is heated to 50 ° C until the solid is completely dissolved. The mixture is filtered hot, then 4.39 kg of purified water are added to the filtrate over one hour, maintaining the temperature at 50 ° C. After initiating the crystallization, the mixture was cooled to 0 and C for 4 hours. The separated crystals are collected by filtration, washed with 0.909 kg and then 0.606 kg of a 1: 2 mixture of ethanol and water, then dried at 38 ° C under reduced pressure (5.07 kPa) in an atmosphere with 80% relative humidity during 48 hours. This is obtained
266,5 g trihydrátu (2R,3S)-4-acetoxy-2a-benzoyloxy-5B,20-epoxy1,7β,10B-trihydroxy-9-oxo-tax-ll-én-13a-yl-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu, pri ktorom sa vysokovýkonnou kvapalinovou chromátografiou stanovila čistota 98,8 % (táto čistota sa vzťahuje k sušine), pričom obsah vody je 6,15 %.266.5 g of (2R, 3S) -4-acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7β, 10B-trihydroxy-9-oxo-tax-11-en-13a-yl-3-tert-butoxycarbonylamino trihydrate 2-hydroxy-3-phenylpropionate, in which a purity of 98.8% (purity related to dry weight) was determined by high performance liquid chromatography, the water content being 6.15%.
Príklad 2Example 2
Pri teplote blízkej 35 °C sa 110,0 g (2R,3S)-4-acetoxy-2abenzoyloxy-5B,20-epoxy-l,7B,10fi-trihydroxy-9-oxo-tax-ll-én-13ayl-3-terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu s čistotou 92,5 % a 0,2224 g kyseliny askorbovej rozpustí v 1340 cm3 etanolu. Oddestiluje sa asi 70 % zavedeného etanolu pri zníženom tlaku (8 kPa) a pri teplote blízkej 20 °C. Zmes sa zohreje na 50 °C a prefiltruje. Filtrát sa trikrát premyje vždy 70,5 cm3 etanolu, následne sa k nemu pridá v priebehu Ϊ5 minút 860,5 cm3 prečistenej vody a to pri teplote 50 °C. Roztok sa zaočkuje niekoľkými kryštálmi trihydrátu (2R,3S)-4acetoxy-2a-benzoyloxy-5B,20-epoxy-l,7B,10B-trihydroxy-9-oxotax-11-én-13 α-y1-3-terc.butoxykarbonylamino-2-hydroxy-3-feny 1propionátu a zmes sa mieša počas 30 minút. Potom sa v priebehu 3 hodín pridá 860,5 cm3 prečistenej vody pri teplote 50 °C, následne sa zmes v priebehu 3 hodín ochladí až na teplotu blízku 0 °C. Suspenzia sa prefiltruje a filtračný koláč sa premyje 330 g zmesi vody a etanolu v hmotnostnom pomere 2:1, následne sa koláč premyje ešte 220 g rovnakej zmesi a potom sa vysuší pri zníženom tlaku (5 kPa) pri teplote 38 °C v atmosfére s 80% relatívnou vlhkosťou. Takto sa získa vo výtažku 98 % 110,2 g trihydrátu (2R,3S)-4-acetoxy-2a-benzoyloxy-5B,20-epoxy-l,7B,10B-trihydroxy-9-oxo-tax-ll-én-13a-yl-3terc.butoxykarbonylamino-2-hydroxy-3-fenylpropionátu.At a temperature close to 35 ° C, 110.0 g of (2R, 3S) -4-acetoxy-2-benzoyloxy-5B, 20-epoxy-1,7B, 10β-trihydroxy-9-oxo-tax-11-en-13ayl-3 of tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate with a purity of 92.5% and 0.2224 g of ascorbic acid are dissolved in 1340 cm 3 of ethanol. About 70% of the ethanol introduced is distilled off under reduced pressure (8 kPa) at a temperature close to 20 ° C. The mixture was heated to 50 ° C and filtered. The filtrate is washed three times with 70.5 cm 3 of ethanol each, followed by 605.5 cm 3 of purified water at 50 ° C over minút5 minutes. The solution is seeded with several crystals of (2R, 3S) -4-acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxotax-11-en-13 α-γ-3-tert-butoxycarbonylamino trihydrate Of 2-hydroxy-3-phenylpropionate and the mixture is stirred for 30 minutes. Thereafter, 860.5 cm @ 3 of purified water are added at 50 DEG C. over a period of 3 hours, followed by cooling to a temperature in the region of 0 DEG C. over 3 hours. The suspension is filtered and the filter cake is washed with 330 g of a 2: 1 mixture of water and ethanol, followed by washing of the cake with 220 g of the same mixture and then dried under reduced pressure (5 kPa) at 38 ° C under 80 % relative humidity. 110.2 g of (2R, 3S) -4-acetoxy-2a-benzoyloxy-5B, 20-epoxy-1,7B, 10B-trihydroxy-9-oxo-tax-11-ene- trihydrate are thus obtained in 98% yield. 13 3terc.butoxykarbonylamino-yl-2-hydroxy-3-phenylpropionate.
Claims (5)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9408479A FR2722191B1 (en) | 1994-07-08 | 1994-07-08 | PROCESS FOR THE PREPARATION OF (2R, 3S) -3-TERTBUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE (2R, 3S) TRIHYDRATE, 20EPOXY-11BYA -13ALPHA-YLE |
| PCT/FR1995/000910 WO1996001815A1 (en) | 1994-07-08 | 1995-07-07 | METHOD FOR PREPARING 4-ACETOXY-2α-BENZOYLOXY-5β,20-EPOXY-1,7β,10β-TRIHYDROXY-9-OXO-TAX-11-EN-13α-YL(2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE TRIHYDRATE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK697A3 true SK697A3 (en) | 1997-06-04 |
| SK280520B6 SK280520B6 (en) | 2000-03-13 |
Family
ID=9465183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK6-97A SK280520B6 (en) | 1994-07-08 | 1995-07-07 | Method for preparing 4-acetoxy-2alpha-benzoyloxy-5alpha,20- -epoxy-1,7beta,10beta-trihydroxy-9-oxo-tax-11-en-13alpha- -yl(2r,3s)-3-tert-butoxycarbonylamino-2-hydroxy-3- -phenylpropionate trihydrate |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US6022985A (en) |
| EP (1) | EP0770070B1 (en) |
| JP (1) | JP3753155B2 (en) |
| KR (1) | KR100391753B1 (en) |
| CN (1) | CN1067996C (en) |
| AT (1) | ATE171702T1 (en) |
| AU (1) | AU706519B2 (en) |
| BR (1) | BR9508789A (en) |
| CA (1) | CA2193531C (en) |
| CO (1) | CO4410189A1 (en) |
| CZ (1) | CZ284695B6 (en) |
| DE (1) | DE69505128T2 (en) |
| DK (1) | DK0770070T3 (en) |
| DZ (1) | DZ1905A1 (en) |
| ES (1) | ES2121404T3 (en) |
| FI (1) | FI119246B (en) |
| FR (1) | FR2722191B1 (en) |
| GR (1) | GR3027558T3 (en) |
| HU (1) | HU220634B1 (en) |
| IL (1) | IL114274A (en) |
| IN (1) | IN183947B (en) |
| IS (1) | IS2032B (en) |
| MA (1) | MA23606A1 (en) |
| MX (1) | MX9700173A (en) |
| MY (1) | MY118481A (en) |
| NO (1) | NO314500B1 (en) |
| NZ (1) | NZ289455A (en) |
| PE (1) | PE8697A1 (en) |
| PL (1) | PL179876B1 (en) |
| RU (1) | RU2126397C1 (en) |
| SI (1) | SI0770070T1 (en) |
| SK (1) | SK280520B6 (en) |
| TN (1) | TNSN95071A1 (en) |
| TW (1) | TW419473B (en) |
| UA (1) | UA51624C2 (en) |
| UY (1) | UY23991A1 (en) |
| WO (1) | WO1996001815A1 (en) |
| ZA (1) | ZA955646B (en) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU753781B2 (en) | 1997-04-28 | 2002-10-31 | Aventis Pharma S.A. | Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors |
| SE510650C2 (en) * | 1997-05-30 | 1999-06-14 | Astra Ab | New association |
| FR2794771B1 (en) | 1999-06-11 | 2001-08-10 | Aventis Pharma Sa | RECOMBINANT ADENOVIRUSES ENCODING THE IODINE SPECIFIC TRANSPORTER (NIS) |
| US6853921B2 (en) | 1999-07-20 | 2005-02-08 | Halliburton Energy Services, Inc. | System and method for real time reservoir management |
| US6266619B1 (en) * | 1999-07-20 | 2001-07-24 | Halliburton Energy Services, Inc. | System and method for real time reservoir management |
| GB9920548D0 (en) * | 1999-08-31 | 1999-11-03 | Rhone Poulenc Rorer Sa | Treatment of hepatocellular carcinoma |
| US6891050B2 (en) * | 2001-08-10 | 2005-05-10 | Dabur India Limited | Process for the preparation of taxanes such as paclitaxel, docetaxel and structurally similar analogs |
| US6881852B2 (en) * | 2002-02-05 | 2005-04-19 | Dabur India Limited | Process of purification of paclitaxel and docetaxel |
| US7247738B2 (en) * | 2002-05-07 | 2007-07-24 | Dabur India Limited | Method of preparation of anticancer taxanes using 3-[(substituted-2-trialkylsilyl) ethoxycarbonyl]-5-oxazolidine carboxylic acids |
| US6900342B2 (en) * | 2002-05-10 | 2005-05-31 | Dabur India Limited | Anticancer taxanes such as paclitaxel, docetaxel and their structural analogs, and a method for the preparation thereof |
| US6838569B2 (en) * | 2002-12-16 | 2005-01-04 | Dabur India Limited | Process for preparation of paclitaxel trihydrate and docetaxel trihydrate |
| US7584165B2 (en) * | 2003-01-30 | 2009-09-01 | Landmark Graphics Corporation | Support apparatus, method and system for real time operations and maintenance |
| US8703982B2 (en) | 2003-03-17 | 2014-04-22 | Phyton Holdings Llc | Purification of taxanes |
| CN1268619C (en) * | 2003-05-08 | 2006-08-09 | 上海迪赛诺化学制药有限公司 | Prepn of polyene taxol trihydrate |
| FR2859996B1 (en) * | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | ACETONIC SOLVAT OF DIMETHOXY DOCETAXEL AND PROCESS FOR PREPARING THE SAME |
| EP1947094A3 (en) | 2003-12-12 | 2009-02-18 | Quiral Quimica Do Brasil | Process for the preparation of taxane derivatives |
| US7142986B2 (en) * | 2005-02-01 | 2006-11-28 | Smith International, Inc. | System for optimizing drilling in real time |
| CN100420681C (en) * | 2005-04-29 | 2008-09-24 | 上海奥锐特国际贸易有限公司 | Production of polyenoic taxad alcohol trihydrate |
| CN101291658B (en) | 2005-08-31 | 2014-04-16 | 阿布拉科斯生物科学有限公司 | Compositions and methods for preparing poorly water-soluble drugs with increased stability |
| US7771751B2 (en) | 2005-08-31 | 2010-08-10 | Abraxis Bioscience, Llc | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
| WO2007044950A2 (en) * | 2005-10-12 | 2007-04-19 | Sicor, Inc. | Crystalline forms of docetaxel and processes for their preparation |
| KR100995390B1 (en) | 2006-01-02 | 2010-11-19 | 주식회사 삼양제넥스 | Method for preparation of amorphous anhydrous crystalline or hydrated crystalline docetaxel |
| WO2007084611A2 (en) * | 2006-01-20 | 2007-07-26 | Landmark Graphics Corporation | Dynamic production system management |
| KR20080100264A (en) * | 2006-03-21 | 2008-11-14 | 닥터 레디스 레보러터리즈 리미티드 | Polymorphs of Docetaxel and Manufacturing Method Thereof |
| EP2330101A1 (en) * | 2006-10-20 | 2011-06-08 | Scinopharm Singapore Pte, Ltd. | Process for making crystalline docetaxel |
| KR100868116B1 (en) * | 2007-04-09 | 2008-11-10 | 한미약품 주식회사 | Docetaxel-monopropylene glycol-containing compound and preparation method thereof |
| KR100878455B1 (en) | 2007-04-10 | 2009-01-13 | 한미약품 주식회사 | Stable anhydrous docetaxel and preparation method thereof |
| WO2009006590A2 (en) * | 2007-07-04 | 2009-01-08 | Dr. Reddy's Laboratories Ltd. | Docetaxel process and polymorphs |
| EP2080763A1 (en) * | 2008-01-18 | 2009-07-22 | INDENA S.p.A. | Crystalline form I of ortataxel |
| EP2080764B1 (en) | 2008-01-18 | 2012-08-22 | INDENA S.p.A. | Solid forms of ortataxel |
| PL388144A1 (en) | 2009-05-29 | 2010-12-06 | Przedsiębiorstwo Produkcyjno-Wdrożeniowe Ifotam Spółka Z Ograniczoną Odpowiedzialnością | (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate 4-acetoxy-2?-benzoiloxy-5� ,20-epoxy-1, 7�, 10�-trihydroxy-9-oxo-taks-11 -en-13?-yl solvates, a method for their production and application thereof |
| US8686165B2 (en) * | 2009-11-04 | 2014-04-01 | Emcure Pharmaceuticals Limited | Process for preparation of taxane derivatives |
| JP5824511B2 (en) | 2010-05-03 | 2015-11-25 | テイコク ファーマ ユーエスエー インコーポレーテッド | Non-aqueous taxane proemulsion formulations and methods for preparing and using the same |
| WO2012160568A1 (en) * | 2011-05-23 | 2012-11-29 | Shilpa Medicare Limited | Process for preparing docetaxel trihydrate polymorph |
| ES2704632T3 (en) | 2011-09-08 | 2019-03-19 | Univ New York | Oncolytic herpes simplex virus and its therapeutic uses |
| US9745631B2 (en) | 2011-12-20 | 2017-08-29 | Dana-Farber Cancer Institute, Inc. | Methods for diagnosing and treating oncogenic kras-associated cancer |
| EP2833905B1 (en) | 2012-04-04 | 2018-05-02 | Halozyme, Inc. | Combination therapy with hyaluronidase and a tumor-targeted taxane |
| AU2013266243A1 (en) | 2012-05-24 | 2014-12-18 | Beth Israel Deaconess Medical Center, Inc. | Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer |
| WO2014014518A1 (en) | 2012-07-18 | 2014-01-23 | Dana-Farber Cancer Institute, Inc. | Methods for treating, preventing and predicting risk of developing breast cancer |
| JO3685B1 (en) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | Non-aqueous taxane nanodispersion formulations and methods of using the same |
| US10238723B2 (en) | 2013-03-14 | 2019-03-26 | Icahn School Of Medicine At Mount Sinai | Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer |
| WO2015050844A1 (en) | 2013-10-01 | 2015-04-09 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancer with atovaquone-related compounds |
| WO2015149006A2 (en) | 2014-03-27 | 2015-10-01 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin |
| MA39818A (en) | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Exogenous tap inhibitor "armed" oncolytic viruses and therapeutic uses thereof |
| EP3307330B1 (en) | 2015-06-15 | 2021-03-10 | New York University | Method of treatment using oncolytic viruses |
| WO2019222435A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601675B1 (en) * | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | TAXOL DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| US5229526A (en) * | 1991-09-23 | 1993-07-20 | Florida State University | Metal alkoxides |
-
1994
- 1994-07-08 FR FR9408479A patent/FR2722191B1/en not_active Expired - Fee Related
-
1995
- 1995-06-22 IL IL11427495A patent/IL114274A/en not_active IP Right Cessation
- 1995-07-03 UY UY23991A patent/UY23991A1/en not_active IP Right Cessation
- 1995-07-04 DZ DZ950082A patent/DZ1905A1/en active
- 1995-07-05 PE PE1995272899A patent/PE8697A1/en not_active IP Right Cessation
- 1995-07-05 TN TNTNSN95071A patent/TNSN95071A1/en unknown
- 1995-07-06 TW TW084106974A patent/TW419473B/en not_active IP Right Cessation
- 1995-07-06 MA MA23945A patent/MA23606A1/en unknown
- 1995-07-06 MY MYPI95001895A patent/MY118481A/en unknown
- 1995-07-06 ZA ZA955646A patent/ZA955646B/en unknown
- 1995-07-06 IN IN1260DE1995 patent/IN183947B/en unknown
- 1995-07-07 ES ES95925022T patent/ES2121404T3/en not_active Expired - Lifetime
- 1995-07-07 CO CO95029779A patent/CO4410189A1/en unknown
- 1995-07-07 AU AU29305/95A patent/AU706519B2/en not_active Expired
- 1995-07-07 KR KR1019970700118A patent/KR100391753B1/en not_active Expired - Lifetime
- 1995-07-07 BR BR9508789A patent/BR9508789A/en not_active Application Discontinuation
- 1995-07-07 EP EP95925022A patent/EP0770070B1/en not_active Expired - Lifetime
- 1995-07-07 CN CN95193984A patent/CN1067996C/en not_active Expired - Lifetime
- 1995-07-07 CZ CZ9735A patent/CZ284695B6/en not_active IP Right Cessation
- 1995-07-07 SK SK6-97A patent/SK280520B6/en not_active IP Right Cessation
- 1995-07-07 NZ NZ289455A patent/NZ289455A/en not_active IP Right Cessation
- 1995-07-07 DK DK95925022T patent/DK0770070T3/en active
- 1995-07-07 RU RU97101875A patent/RU2126397C1/en active
- 1995-07-07 MX MX9700173A patent/MX9700173A/en unknown
- 1995-07-07 JP JP50415896A patent/JP3753155B2/en not_active Expired - Fee Related
- 1995-07-07 SI SI9530138T patent/SI0770070T1/en unknown
- 1995-07-07 US US08/776,333 patent/US6022985A/en not_active Expired - Lifetime
- 1995-07-07 PL PL95318195A patent/PL179876B1/en unknown
- 1995-07-07 UA UA97010077A patent/UA51624C2/en unknown
- 1995-07-07 AT AT95925022T patent/ATE171702T1/en active
- 1995-07-07 DE DE69505128T patent/DE69505128T2/en not_active Expired - Lifetime
- 1995-07-07 HU HU9700041A patent/HU220634B1/en unknown
- 1995-07-07 CA CA002193531A patent/CA2193531C/en not_active Expired - Lifetime
- 1995-07-07 WO PCT/FR1995/000910 patent/WO1996001815A1/en not_active Ceased
-
1997
- 1997-01-02 NO NO19970007A patent/NO314500B1/en not_active IP Right Cessation
- 1997-01-07 IS IS4411A patent/IS2032B/en unknown
- 1997-01-07 FI FI970069A patent/FI119246B/en not_active IP Right Cessation
-
1998
- 1998-01-01 GR GR980400355T patent/GR3027558T3/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK280520B6 (en) | Method for preparing 4-acetoxy-2alpha-benzoyloxy-5alpha,20- -epoxy-1,7beta,10beta-trihydroxy-9-oxo-tax-11-en-13alpha- -yl(2r,3s)-3-tert-butoxycarbonylamino-2-hydroxy-3- -phenylpropionate trihydrate | |
| USRE36433E (en) | Process for the purifying of iopamidol | |
| EP0976750A1 (en) | Novel z-valacyclovir crystals | |
| JP3521242B2 (en) | Purification method of biscresols | |
| US6037494A (en) | Process for the crystallization from a linear or branched (C5-C6) alcohol or their mixtures of (S)-N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyy l)amino]-2,4,6-triiodo-1,3-benzendicarboxamide | |
| US5338869A (en) | Hydroxyphenylpropionic ester having novel crystal structure | |
| US4868312A (en) | N.sup.ε -trifluoroacetyl-L-lysyl-L-proline.D-10-camphorsulfonic acid salt and process for producing the same | |
| SU1034605A3 (en) | Process for preparing molecular compound of beta-diethylaminoethylamide of n-chloroacetic phenoxy acid with 4-n-butyl-3,5-diketo-1,2-diphenylpyrazolidine | |
| JP4694018B2 (en) | Method for purifying mevalolactone methacrylate | |
| US6235775B1 (en) | Acetone adduct of fungicidal V-28-3M | |
| JPH10109991A (en) | Production of dimethylamine-borane | |
| JPH07224052A (en) | Method for purifying 2-oxetanone | |
| WO2016142173A1 (en) | 4-(2-methyl-1h-imidazol-1-yl)-2,2-diphenylbutanenitrile solid form | |
| CN109879739A (en) | A kind of refining methd of terephthalaldehyde | |
| CS254347B2 (en) | Method of 19-deoxyagglycondianemycine's water-free sodium salt production | |
| JPH09157268A (en) | Production of 7-hydroxyisoflavone and its purification | |
| MXPA97007146A (en) | Procedure for the obtaining of dimethylaminobor | |
| JPH023628A (en) | Production of optically active 1-methyl-3-phenylpropylamine | |
| KR20000053467A (en) | Process for recrystallizing 1,3-bis(aminophenoxy benzene) | |
| CS233413B1 (en) | Method of purification of 2-chloro-5- [1-hydroxy-3-oxo-1-isoindolinyl] benzanesulfonamide | |
| JPWO1999014225A1 (en) | Acetone adduct of antifungal agent V-28-3M | |
| JPH0135820B2 (en) | ||
| JPS5837307B2 (en) | L-pyroglutamyl-L-histidyl-L-prolinamide/L-pyroglutamate | |
| JPH06135918A (en) | Method for separating N, O-dialkylhydroxylamine hydrochloride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| QB4A | Licence contract registered or granted |
Free format text: EXCLUSIVE LICENCE Name of requester: MAY & BAKER LTD., WEST MALLING, KENT, GB Effective date: 20070101 Free format text: NON-EXCLUSIVE LICENCE Name of requester: SANOFI-AVENTIS PHARMA SLOVAKIA S.R.O., BRATISL, SK Effective date: 20100420 |
|
| MK4A | Patent expired |
Expiry date: 20150707 |